The expression of miR-22, miR-140, and miR-328 in breast cancer tissues: Implications for PET/CT imaging biomarkers

Basit Öğe Kaydı
dc.authorid0000-0003-4303-9717
dc.contributor.authorGokce, Elif Ozlem
dc.contributor.authorCicekliyurt, Meliha Merve
dc.contributor.authorGokce, Oruc Numan
dc.contributor.authorCetin, Kenan
dc.date.accessioned2026-02-03T11:59:42Z
dc.date.available2026-02-03T11:59:42Z
dc.date.issued2025
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractAim: To evaluate the correlation between microRNA (miRNA) expression and 18F-fluorodeoxyglucose (18F-FDG) uptake in breast cancer patients, focusing on the tumor-suppressor miRNAs miR-22, miR-140, and miR-328, and their potential as diagnostic biomarkers. Material and Methods: Biopsies from 14 female breast cancer patients were analyzed, including both tumor and adjacent healthy tissues. The expression levels of miR-22, miR-140, and miR-328 were quantified using real-time PCR. SUVmax values from PET/CT imaging were obtained to assess metabolic activity in tumor tissues. Statistical analyses were performed to explore correlations between miRNA expression and PET/CT results. Results: Our patients' ages ranged from 38 to 74 years, with a mean of 59.5 years. The levels of miR-22, miR-328, and miR-140 were significantly lower in breast cancer tissues compared to healthy tissues. However, no statistically significant correlations were found between miRNA values and 18-FDG PET/CT SUVmax values. Discussion: While miR-22, miR-140, and miR-328 show promise as potential diagnostic biomarkers for breast cancer due to their significant downregulation in tumor tissues, their expression does not correlate with metabolic activity as measured by SUVmax in PET/CT imaging. Further research is needed to explore the clinical applications of miRNAs in breast cancer diagnosis and prognosis.
dc.description.sponsorshipScientific Research Coordination Unit [TYL-2022-3842]
dc.description.sponsorshipThis work was supported by Canakkale Onsekiz Mart University's Scientific Research Coordination Unit, Project number: TYL-2022-3842.r Scientific Research Coordination Unit, Project number: TYL-2022-3842.
dc.identifier.doi10.4328/ACAM.22454
dc.identifier.endpage419
dc.identifier.issn2667-663X
dc.identifier.issue6
dc.identifier.startpage415
dc.identifier.urihttps://doi.org/10.4328/ACAM.22454
dc.identifier.urihttps://hdl.handle.net/20.500.12428/34389
dc.identifier.volume16
dc.identifier.wosWOS:001518248400007
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherBayrakol Medical Publisher
dc.relation.ispartofAnnals of Clinical and Analytical Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20260130
dc.subjectBreast Cancer
dc.subjectGlut
dc.subjectMir-22
dc.subjectMir-328
dc.subjectMir-140
dc.subjectPET/CT
dc.titleThe expression of miR-22, miR-140, and miR-328 in breast cancer tissues: Implications for PET/CT imaging biomarkers
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu